Fig. 1From: Prognostic values of mid-radiotherapy 18F-FDG PET/CT in patients with esophageal cancerClinical outcomes for the entire cohort. Progression-free survival, overall survival (a), locoregional recurrence-free rate (LRFR), and distant metastasis-free rate (DMFR) (b) for the entire cohortBack to article page